NASDAQ:ESPR - Esperion Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$43.64 +1.64 (+3.90 %)
(As of 01/23/2019 11:01 AM ET)
Previous Close$42.00
Today's Range$41.77 - $43.64
52-Week Range$33.06 - $82.68
Volume6,669 shs
Average Volume681,785 shs
Market Capitalization$1.17 billion
P/E Ratio-6.23
Dividend YieldN/A
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ESPR



Sales & Book Value

Annual SalesN/A
Book Value$9.34 per share


Net Income$-166,980,000.00


Market Cap$1.17 billion

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.58) by $0.28. During the same period in the prior year, the business earned ($1.86) earnings per share. View Esperion Therapeutics' Earnings History.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 19th 2019. View Earnings Estimates for Esperion Therapeutics.

What price target have analysts set for ESPR?

14 equities research analysts have issued 12 month price targets for Esperion Therapeutics' shares. Their predictions range from $32.50 to $153.00. On average, they anticipate Esperion Therapeutics' share price to reach $79.1154 in the next year. This suggests a possible upside of 81.3% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.

What is the consensus analysts' recommendation for Esperion Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 3 sell ratings, 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (11/6/2018)
  • 2. Chardan Capital analysts commented, "We revise our p-value estimate on the imbalance of deaths seen in the pooled phase II/III data for bempedoic acid (BA) from p<0.05 to p=0.06-0.11 after consulting separately with 3 professional biostatisticians. We remain cautious on ESPR and upcoming Study 2 phase III data in September (see page 2). Esperion reported positive efficacy data from the 52-week phase III study (Study 1; NCT02666664) of BA in 2,230 inadequately-treated ASCVD patients. However, the company reported an imbalance of deaths in Study 1, namely 13 deaths (0.87%, 13/1,488) in the BA-treated group, vs. 2 deaths (0.27%, 2/742) in the placebo-treated group. Since Esperion provided no p-value on this imbalance of deaths, and because there was to us insufficient information on the exact nature of deaths (e.g."" (7/20/2018)

Has Esperion Therapeutics been receiving favorable news coverage?

Headlines about ESPR stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Esperion Therapeutics earned a news impact score of 1.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Esperion Therapeutics' key competitors?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the folowing people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
  • Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
  • Ms. Marianne Andreach, Sr. VP of Product Planning

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Meditor Group Ltd (10.00%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Dov A Md Goldstein, Gilbert S Omenn, Nicole Vitullo, Roger S Newton and Target N V Biotech. View Institutional Ownership Trends for Esperion Therapeutics.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was purchased by a variety of institutional investors in the last quarter, including Meditor Group Ltd. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn and Target N V Biotech. View Insider Buying and Selling for Esperion Therapeutics.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $43.64.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $1.17 billion. The biopharmaceutical company earns $-166,980,000.00 in net income (profit) each year or ($6.98) on an earnings per share basis. Esperion Therapeutics employs 57 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  444 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  806
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel